Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385400575> ?p ?o ?g. }
- W4385400575 endingPage "3887" @default.
- W4385400575 startingPage "3887" @default.
- W4385400575 abstract "Synovial sarcoma (SyS) is a rare aggressive soft tissue sarcoma carrying the chromosomal translocation t(X;18), encoding the fusion transcript SS18::SSX. The fusion oncoprotein interacts with both BAF enhancer complexes and polycomb repressor complexes, resulting in genome-wide epigenetic perturbations and a unique altered genetic signature. Over 80% of the patients are initially diagnosed with localized disease and have a 5-year survival rate of 70–80%, but metastatic relapse occurs in 50% of the cases. Advanced, unresectable, or metastatic disease has a 5-year survival rate below 10%, representing a critical issue. This review summarizes the molecular mechanisms behind SyS and illustrates current treatments in front line, second line, and beyond settings. We analyze the use of immune check point inhibitors (ICI) in SyS that do not behave as an ICI-sensitive tumor, claiming the need for predictive genetic signatures and tumor immune microenvironment biomarkers. We highlight the clinical translation of innovative technologies, such as proteolysis targeting chimera (PROTAC) protein degraders or adoptive transfer of engineered immune cells. Adoptive cell transfer of engineered T-cell receptor cells targeting selected cancer/testis antigens has shown promising results against metastatic SyS in early clinical trials and further improvements are awaited from refinements involving immune cell engineering and tumor immune microenvironment enhancement." @default.
- W4385400575 created "2023-07-31" @default.
- W4385400575 creator A5015636061 @default.
- W4385400575 creator A5025533934 @default.
- W4385400575 creator A5043283322 @default.
- W4385400575 creator A5047346473 @default.
- W4385400575 creator A5083920182 @default.
- W4385400575 date "2023-07-30" @default.
- W4385400575 modified "2023-10-14" @default.
- W4385400575 title "Innovative Breakthroughs for the Treatment of Advanced and Metastatic Synovial Sarcoma" @default.
- W4385400575 cites W1968408039 @default.
- W4385400575 cites W1970087181 @default.
- W4385400575 cites W1990255585 @default.
- W4385400575 cites W2005686017 @default.
- W4385400575 cites W2013286412 @default.
- W4385400575 cites W2025847887 @default.
- W4385400575 cites W2038195711 @default.
- W4385400575 cites W2038208403 @default.
- W4385400575 cites W2038576760 @default.
- W4385400575 cites W2050651740 @default.
- W4385400575 cites W2056955003 @default.
- W4385400575 cites W2062906902 @default.
- W4385400575 cites W2112169652 @default.
- W4385400575 cites W2117431699 @default.
- W4385400575 cites W2118475754 @default.
- W4385400575 cites W2140719387 @default.
- W4385400575 cites W2143530174 @default.
- W4385400575 cites W2165119413 @default.
- W4385400575 cites W2166268454 @default.
- W4385400575 cites W2294375233 @default.
- W4385400575 cites W2472687861 @default.
- W4385400575 cites W2485005154 @default.
- W4385400575 cites W2537836937 @default.
- W4385400575 cites W2554618897 @default.
- W4385400575 cites W2566818944 @default.
- W4385400575 cites W2618374662 @default.
- W4385400575 cites W2762797139 @default.
- W4385400575 cites W2806892701 @default.
- W4385400575 cites W2807603420 @default.
- W4385400575 cites W2808647193 @default.
- W4385400575 cites W2883345755 @default.
- W4385400575 cites W2890921517 @default.
- W4385400575 cites W2898224297 @default.
- W4385400575 cites W2967300456 @default.
- W4385400575 cites W2976965032 @default.
- W4385400575 cites W2981264938 @default.
- W4385400575 cites W2981595408 @default.
- W4385400575 cites W2990304685 @default.
- W4385400575 cites W3000282923 @default.
- W4385400575 cites W3003310139 @default.
- W4385400575 cites W3010223792 @default.
- W4385400575 cites W3015451486 @default.
- W4385400575 cites W3028057802 @default.
- W4385400575 cites W3048712150 @default.
- W4385400575 cites W3049319048 @default.
- W4385400575 cites W3092409743 @default.
- W4385400575 cites W3092440661 @default.
- W4385400575 cites W3113722698 @default.
- W4385400575 cites W3121990740 @default.
- W4385400575 cites W3137067885 @default.
- W4385400575 cites W3157618208 @default.
- W4385400575 cites W3159602776 @default.
- W4385400575 cites W3161211885 @default.
- W4385400575 cites W3165671677 @default.
- W4385400575 cites W3168412060 @default.
- W4385400575 cites W3175051117 @default.
- W4385400575 cites W3211375979 @default.
- W4385400575 cites W4200056901 @default.
- W4385400575 cites W4200604074 @default.
- W4385400575 cites W4205379795 @default.
- W4385400575 cites W4213244257 @default.
- W4385400575 cites W4225414386 @default.
- W4385400575 cites W4225670774 @default.
- W4385400575 cites W4281563307 @default.
- W4385400575 cites W4281719775 @default.
- W4385400575 cites W4283029304 @default.
- W4385400575 cites W4293116302 @default.
- W4385400575 cites W4293860952 @default.
- W4385400575 cites W4294958151 @default.
- W4385400575 cites W4294970407 @default.
- W4385400575 cites W4309360344 @default.
- W4385400575 cites W4313893438 @default.
- W4385400575 cites W4317434533 @default.
- W4385400575 cites W4317930013 @default.
- W4385400575 cites W4318822890 @default.
- W4385400575 cites W4318917475 @default.
- W4385400575 cites W4319597836 @default.
- W4385400575 cites W4323036781 @default.
- W4385400575 cites W4324150379 @default.
- W4385400575 doi "https://doi.org/10.3390/cancers15153887" @default.
- W4385400575 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37568703" @default.
- W4385400575 hasPublicationYear "2023" @default.
- W4385400575 type Work @default.
- W4385400575 citedByCount "0" @default.
- W4385400575 crossrefType "journal-article" @default.
- W4385400575 hasAuthorship W4385400575A5015636061 @default.
- W4385400575 hasAuthorship W4385400575A5025533934 @default.
- W4385400575 hasAuthorship W4385400575A5043283322 @default.